Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

618 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H, Takashima A, Yokota M, Makiyama A, Akazawa N, Ojima H, Yuasa Y, Miwa K, Yasui H, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Hihara M, Soeda J, Misumi T, Yamamoto K, Akagi K, Ochiai A, Uetake H, Tsuchihara K, Yoshino T. Watanabe J, et al. Among authors: oki e. JAMA. 2023 Apr 18;329(15):1271-1282. doi: 10.1001/jama.2023.4428. JAMA. 2023. PMID: 37071094 Free PMC article. Clinical Trial.
[Chemotherapy for gastric cancer].
Baba H, Kakeji Y, Oki E, Tokunaga E, Ushiro S, Watanabe M, Maehara Y. Baba H, et al. Among authors: oki e. Gan To Kagaku Ryoho. 2003 Nov;30(12):1881-8. Gan To Kagaku Ryoho. 2003. PMID: 14650954 Review. Japanese.
A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience.
Ogata Y, Tokunaga S, Emi Y, Oki E, Saeki H, Shirabe K, Hasegawa H, Sadanaga N, Samura H, Fujita F, Tanaka T, Kitazono M, Yamamoto M, Morikita T, Inomata M, Kakeji Y, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer. Ogata Y, et al. Among authors: oki e. Surg Today. 2011 Jan;41(1):84-90. doi: 10.1007/s00595-010-4418-6. Epub 2010 Dec 30. Surg Today. 2011. PMID: 21191696 Clinical Trial.
A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience.
Baba H, Hayashi N, Emi Y, Kakeji Y, Egashira A, Oki E, Shirabe K, Toyama T, Ohga T, Yamamoto M, Hasegawa H, Kohakura F, Higashi H, Niwa K, Fujita F, Ogata Y, Kohnoe S, Inomata M, Samura H, Tokunaga S, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC). Baba H, et al. Among authors: oki e. Surg Today. 2011 Dec;41(12):1610-6. doi: 10.1007/s00595-011-4589-9. Epub 2011 Oct 4. Surg Today. 2011. PMID: 21969193 Clinical Trial.
Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701).
Oki E, Emi Y, Akagi Y, Tokunaga S, Sadanaga N, Tanaka T, Ogata Y, Saeki H, Kakeji Y, Baba H, Nishimaki T, Natsugoe S, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer. Oki E, et al. Oncology. 2013;84(4):233-9. doi: 10.1159/000346690. Epub 2013 Jan 31. Oncology. 2013. PMID: 23392220 Clinical Trial.
Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Imai K, Emi Y, Iyama KI, Beppu T, Ogata Y, Kakeji Y, Samura H, Oki E, Akagi Y, Maehara Y, Baba H; Kyusyu Study Group of Clinical Cancer (KSCC) ancillary study. Imai K, et al. Among authors: oki e. Eur J Surg Oncol. 2014 May;40(5):559-566. doi: 10.1016/j.ejso.2013.12.009. Epub 2013 Dec 20. Eur J Surg Oncol. 2014. PMID: 24388740
Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study).
Beppu T, Emi Y, Tokunaga S, Oki E, Shirabe K, Ueno S, Kuramoto M, Kabashima A, Takahashi I, Samura H, Eguchi S, Akagi Y, Natsugoe S, Ogata Y, Kakeji Y, Baba H, Maehara Y; Kyushu Study group of Clinical Cancer (KSCC). Beppu T, et al. Among authors: oki e. Anticancer Res. 2014 Nov;34(11):6655-62. Anticancer Res. 2014. PMID: 25368271
Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.
Oki E, Emi Y, Kojima H, Higashijima J, Kato T, Miyake Y, Kon M, Ogata Y, Takahashi K, Ishida H, Saeki H, Sakaguchi Y, Yamanaka T, Kono T, Tomita N, Baba H, Shirabe K, Kakeji Y, Maehara Y. Oki E, et al. Int J Clin Oncol. 2015 Aug;20(4):767-75. doi: 10.1007/s10147-015-0784-9. Epub 2015 Jan 28. Int J Clin Oncol. 2015. PMID: 25627820 Clinical Trial.
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
Miwa K, Oki E, Emi Y, Saeki H, Kusumoto T, Akagi Y, Ogata Y, Samura H, Tokunaga S, Ishikawa H, Tanaka T, Sueyoshi S, Higashi H, Matsuda H, Touyama T, Maehara Y; Kyushu Study Group of Clinical Cancer. Miwa K, et al. Among authors: oki e. Int J Clin Oncol. 2016 Feb;21(1):110-7. doi: 10.1007/s10147-015-0850-3. Epub 2015 Jun 3. Int J Clin Oncol. 2016. PMID: 26037783 Clinical Trial.
618 results